Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. | CEO, MD & Director | 377.81k | -- | 1964 |
| Mr. Timothy Luscombe B.Com., C.A. | Chief Financial Officer | -- | -- | -- |
| Ms. Rhiannon Jones B.Sc., Ph.D. | Chief Operating Officer | -- | -- | -- |
| Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD | Company Secretary | 76.67k | -- | 1960 |
Amplia Therapeutics Limited
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Corporate Governance
Upcoming Events
May 28, 2025 at 8:40 AM UTC - June 2, 2025 at 8:40 AM UTC
Amplia Therapeutics Limited Earnings Date
Recent Events
Recent Events Information Not Available